

AMENDMENTS TO THE DRAWINGS

Kindly replace Figure 5 with the replacement sheet submitted herewith.

REMARKS

The title has been amended and a paragraph cross-referencing related applications has been added. The paragraph starting at page 7, line 23 of the English language specification has been amended to recite “pCAGGS-NP.” Support for this amendment is found, for example, from page 38, line 25 to page 39, line 15. The paragraph starting at page 12, line 12 has been amended to recite the term “exogenous.” This amendment is made for purposes of clarification and is supported, for example, by page 12, lines 12-14. The paragraph starting at page 17, line 27 has been amended to recite a corrected final page number for the reference cited. This amendment corrects a typographical error that is obvious if one refers to the actual page numbers of the cited reference. The paragraph starting at page 18, line 28 has been amended to recite “Gaps outside of SEQ ID NO: 17 or 18.” Support for this amendment is found, for example, from page 18, line 28 to page 19, line 14, which discusses the determination of sequence identity with the nucleotide sequence of SEQ ID NO: 17 or 18. The paragraph starting at page 20, line 36 has been amended to recite “modified viral protein.” Support for this amendment is found, for example, from page 20, line 36 to page 21, line 11, which describes a vector that expresses a modified viral protein in a recombination enzyme-dependent manner. The paragraph starting at page 23, line 5 has been amended to remove references to Orthomyxoviridae, Bunyaviridae, and Arenaviridae. This amendment is based on the known fact that viruses belonging to Orthomyxoviridae, Bunyaviridae, and Arenaviridae

are minus-strand RNA viruses, but not single-stranded minus-strand RNA viruses. The paragraph starting at page 32, line 36 has been amended to recite “a T7 RNA polymerase-expressing plasmid (for example, 0.5µg)”; “pCAGGS-T7 for example, 0.5µg”; “pSeV(TDK)18+GFP”; and “(pSeV/ΔF-GFP).” Support for this amendment is found, for example, on page 40, lines 13-21, and in Examples 6 and 7 (particularly page 44, lines 32-34; and page 45, line 18-20). Claim 27 has been amended for purposes of clarification. Support for this amendment is found, for example, from page 15, line 27 to page 16, line 2. Figure 5 has been amended to recite “CONSTRUCTION OF pCAGGS-NP.” Support for this amendment is found, for example, at the bottom of original Figure 5, as the final construct is named “pCAGGS-NP.” Finally, applicants include a sequence listing, based on the sequence listing as filed with WIPO, in which the bibliographic and priority information has been updated.


No new matter has been added by the present amendment.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 24 July 2006



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045